Eli Lilly Strikes $3.2 Billion Deal to Acquire Morphic
Eli Lilly (LLY) will buy biopharmaceutical company Morphic (MORF) for roughly $3.2 billion in a bid to expand its immunology portfolio with oral therapies targeting cell proteins for chronic diseases.
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
A Quick Look at Today's Ratings for Morphic(MORF.US), With a Forecast Between $57 to $64
On Jul 09, major Wall Street analysts update their ratings for $Morphic(MORF.US)$, with price targets ranging from $57 to $64.Wells Fargo analyst Derek Archila maintains with a buy rating, and
Express News | RBC Capital Downgrades Morphic Holding to Sector Perform, Lowers Price Target to $57
Morphic Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 1.42% RBC Capital $70 → $57 Downgrades Outperform → Sector Perform 03/08/2024 17.44%
TD Cowen Downgrades Morphic Holding to Hold From Buy
Morphic Holding (MORF) has an average rating of outperform and price targets ranging from $30 to $64, according to analysts polled by Capital IQ.Price: 55.80, Change: +0.06, Percent Change: +0.11
Morphic Holding Acquisition Prospects: A Balanced Hold Rating Amid Lilly's Offer and Pipeline Potential
Express News | Morphic Holding Inc : BMO Raises Target Price to $57 From $52
Express News | Morphic Holding Inc : BMO Cuts to Market Perform From Outperform
Morphic Holding (MORF) Was Downgraded to a Hold Rating at RBC Capital
Analysts Conflicted on These Healthcare Names: HilleVax, Inc (HLVX), UnitedHealth (UNH) and Morphic Holding (MORF)
Favorable Outlook for Eli Lilly's Acquisition of Morphic Holding With Strong Prospects for MORF-057
Express News | Morphic Holding Inc : TD Cowen Cuts to Hold From Buy
S&P 500 Closes At Record High Ahead Of Inflation Data: Fear & Greed Index Remains In 'Neutral' Zone
The CNN Money Fear and Greed index showed a slight decline in the overall market sentiment, while the index remained in the "Neutral" zone on Monday.U.S. stocks closed mixed on Monday, with the S&P 50
Express News | Morphic Holding Inc : RBC Cuts to Sector Perform From Outperform; Cuts Target Price to $57 From $70
Eli Lilly and Co acquired Morphic at a 79% premium for $3.2 billion, causing a 75% surge in stocks.
Doubling down on the IBD track.
Morphic Holding (MORF) Was Downgraded to a Hold Rating at TD Cowen
US stocks hit new highs, with Apple's market cap surpassing Microsoft's, Tesla rising for the ninth consecutive day, silver futures falling by 3% at one point, and French stocks opening high and falling low.
Waiting for this week's US CPI and PPI inflation and Powell's congressional hearing. The New York Fed survey found that Americans' inflation expectations have fallen for two consecutive months, and the market is still betting on two interest rate cuts later this year. The S&P and Nasdaq have hit new highs for at least four days in a row, and Apple's market cap has surpassed Microsoft to become the largest company. Nvidia's increase has been cut in half after a nearly 4% increase, and TSMC briefly rose more than 4.8% in market cap, breaking the $1 trillion barrier. AI concept stocks such as Arm and Oracle also hit new highs and Intel and Super Micro Computer rose more than 6%. The Chinese concept stock index fell 1%, Xpeng Motors fell more than 6%, and Niu Technologies rose 16%. The second round of the French parliament elections unexpectedly ended without any political party obtaining an absolute majority, and European stocks rose but fell in the final session. The euro and French bond yields also opened high
Health Care Flat Amid Deal Activity -- Health Care Roundup
Health-care companies were flat amid deal activity. Shares of Morphic Holdings rallied after drug giant Eli Lilly agreed to buy the biopharmaceutical company for $3.2 billion, paying a hefty premium f
News Highlights: Top Company News of the Day - Monday at 5 PM ET
Eli Lilly to Buy Morphic Holding for $3.2 Billion Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the drugmaker's immunology pipeline. Bo